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Abstract
Background: Mesenchymal stem cells (MSC) are currently strong candidates for cell-based therapies. They are well known
for their differentiation potential and immunoregulatory properties and have been proven to be potentially effective in the
treatment of a large variety of diseases, including neurodegenerative disorders. Currently there is no treatment that
provides consistent long-term benefits for patients with multiple system atrophy (MSA), a fatal late onset a-
synucleinopathy. Principally neuroprotective or regenerative strategies, including cell-based therapies, represent a powerful
approach for treating MSA. In this study we investigated the efficacy of intravenously applied MSCs in terms of behavioural
improvement, neuroprotection and modulation of neuroinflammation in the (PLP)-asynuclein (aSYN) MSA model.
Methodology/Principal Findings: MSCs were intravenously applied in aged (PLP)-aSYN transgenic mice. Behavioural
analyses, defining fine motor coordination and balance capabilities as well as stride length analysis, were performed to
measure behavioural outcome. Neuroprotection was assessed by quantifying TH neurons in the substantia nigra pars
compacta (SNc). MSC treatment on neuroinflammation was analysed by cytokine measurements (IL-1a, IL-2, IL-4, IL-5, IL-6,
IL-10, IL-17, GM-CSF, INFc, MCP-1, TGF-b1, TNF-a) in brain lysates together with immunohistochemistry for T-cells and
microglia. Four weeks post MSC treatment we observed neuroprotection in the SNc, as well as downregulation of
cytokines involved in neuroinflammation. However, there was no behavioural improvement after MSC application.
Conclusions/Significance: To our knowledge this is the first experimental approach of MSC treatment in a transgenic MSA mouse
model. Our data suggest that intravenously infused MSCs have a potent effect on immunomodulation and neuroprotection. Our
data warrant further studies to elucidate the efficacy of systemically administered MSCs in transgenic MSA models.
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Introduction
Multiple system atrophy (MSA) denotes an adult-onset neurode-
generative disorder of relentless progression and unknown aetiology
that is clinically characterized by the variable combination of
autonomic failure, levodopa-unresponsive parkinsonism, cerebellar
ataxia, and pyramidal signs. MSA affects men and woman equally,
usuallystartinginthe sixthdecadeandprogressesrapidlywithdeath
occurring after an average of nine years [1]. Pathological features
cover selective neuronal cell loss and gliosis in the basal ganglia,
cerebellum, pontine and inferior olivary nuclei, pyramidal tract,
intermediolateral cell column and Onuf’s nucleus [2].
Morphologically, MSA is considered a primary oligodendro-
gliopathy based on the cellular hallmark, the glial cytoplasmic
inclusions (GCIs) [3]. GCIs contain primarily a-synuclein (aSYN)
and hence link MSA with other a-synucleinopathies, such as
Parkinson’s disease (PD) and dementia with Lewy Bodies (DLB)
[4,5]. Still the underlying mechanism of aSYN aggregates, which
appear to play a fundamental role in disease pathogenesis, remains
to be determined. However, several molecular and cellular
changes, including oxidative stress, mitochondrial dysfunction
and apoptotic processes might be involved in neuronal degener-
ation [1,6,7].
Microglial activation has been reported to parallel the neuronal
multisystem degeneration in MSA [8], suggesting neuroinflamma-
tion as a key pathogenic mechanism comparable to findings in PD
[9]. During the last years, studies analysing polymorphism of genes
involved in inflammatory processes, such as interleukin-1alpha
(IL-a), interleukin-1beta (IL-1b), interleukin-8, intercellular adhe-
sion molecule-1 and tumor necrosis factor showed elevated MSA
risk [10]. These studies point towards a possible role of
neuroinflammation in MSA pathogenesis.
At present, MSA therapy is only symptomatic and mainly
targets parkinsonism and autonomic failure [2] as there is no drug
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benefits. Neuroprotective or regenerative strategies, including
neurotransplantation, appear to be an alternative therapeutic
approach for managing MSA patients. Experimentally, different
cell types for neural restoration in MSA have been tried. E13
whole ganglionic eminence grafts survive and exert functional
benefit in toxin-based MSA models [11–13]. Moreover, survival,
integration and functional benefit of E13 ventral mesencephalic
(VM) grafts in toxin-based MSA models has been demonstrated
[14] .
A particular type of stem cells which is considered clinically
more attractive, ethically less problematic and exhibiting immu-
nological properties that make them superior over other cell types
are mesenchymal stem cells (MSCs). First described by Frieden-
stein and colleagues [15], as a population of bone marrow (BM)
cells, also known as fibroblast-colony-forming cells, which adhere
to cell culture plastic surfaces, these cells were shown to
differentiate into many mesodermal derivatives, such as adipo-
cytes, osteocytes and chondrocytes, in vitro and in vivo when
exposed to appropriate stimuli [16,17].
The MSCs’ ability to differentiate into neural-like and glial-like
cells could be shown, albeit in vitro only [18,19]. Based on this and
similar results, subsequent studies have been initiated and designed
in order to prove these cells’ potential to support neuroregenera-
tion and also to provoke their immunomodulatory properties in
regions, which are actually void of MSC (reviewed in [20]). This
particular body of literature is vastly growing, yet lacking strong in
vivo evidence which demonstrates that MSCs, unless they are
ectopically placed there or infused in large numbers, are indeed
capable of bringing forth neuro-ectodermal derivatives. In light of
this, many findings and interpretations remain elusive [21].
Long-term clinical and radiological effects of MSCs in patients
with MSA have been described by Lee and co-workers in 2008
[22]. In an open-label study design, the neurological deficits in 11
patients with the cerebellar type of MSA (MSA-C), who received
consecutively intra-arterial and three repeated intravenous injec-
tions for three months, were compared with non-treated MSA
patients, demonstrating a delay in progression of neurological
deficits after MSC therapy [22]. A recent study by the same group
investigated successful neuroprotective and immunomodulatory
effects of human MSCs in a double-toxin induced animal model of
MSA-P [23]. However this double-toxin induced model solely
represents striatonigral-like pathology, without reproducing oligo-
dendroglial inclusion pathology, mediating secondary neuronal
multisystem degeneration [3].
At present to our knowledge, there is no experimental evidence
for the neuroregenerative potential of MSCs in transgenic mice,
overexpressing oligodendroglial aSYN, mimicking important
aspects of MSA, such as neuronal loss linked to MSA-like
progressive autonomic failure, cerebellar ataxia and parkinsonism,
GCI pathology, astrogliosis and microglial activation. For this
reason we applied murine MSCs intravenously in aged (PLP)-
aSYN transgenic mice and analysed possible neuroprotective
effects and the capacity of modulating neuroinflammation.
Methods
Animals
In the present study homozygous (PLP)-a-SYN mice [24] at the
age of 18 months were used. The animal study was designed
compliant with the Austrian guidelines for the care and use of
laboratory animals and all experiments were approved by the
Federal Ministry for Education, Science and Research of Austria
with the reference number do. ZI. 5004. Animals were housed at
the Animal Facility of the Innsbruck Medical University under a
12-hour light/dark cycle with food and water available ad libitum.
Isolation of GFP MSCs
MSCs were obtained from C57BL/6-Tg(UBC-GFP)30Scha/J
mice (Charles River, Germany), 6–8 weeks old, expressing the
enhanced green fluorescent protein (GFP) gene under the human
ubiquitin C promoter [25]. Primary GFP mMSC cultures were
isolated according to established protocols [26].
Briefly, tibia and femur were treated with collagenase (Sigma,
St. Louis, MO, USA) for 2 h, 37uC, 20% O2,5 %C O 2.
Thereafter, fragmented bones were centrifuged and cell fractions
were loaded on a Ficoll-Paque Plus gradient (Amersham
Biosciences, Piscataway, NJ, USA) to harvest cells from the
interphase, followed by a washing step. The isolated bone marrow
cells were seeded for expansion in complete isolation medium
constituted of RPMI-1640 (Gibco, Invitrogen, Carlsbad, Ca, USA)
supplemented with 20% fetal bovine serum (Invitrogen), 100
units/ml penicillin and 100 mg/ml streptomycin (Invitrogen). After
24 hours non-adhering cells were removed by extensive washing
with Dulbecco’s phosphate buffered saline (DPBS Invitrogen). The
attached cells were cultured until confluent and subsequently
subcultured at low density (50 cells/cm
2) with complete expansion
medium consistent of Iscove’s Modified Dulbecco’s Medium
(IMDM, Invitrogen) supplemented with 20% fetal bovine serum
(Invitrogen), 100 units/ml penicillin and 100 mg/ml streptomycin
(Invitrogen). Medium exchange was performed twice weekly.
Characterization of GFP MSCs by flow cytometry
GFP MSCs were washed with DPBS, harvested with 0.25%
trypsin and 1 mM EDTA (Invitrogen) for five minutes at 37uC,
divided into round-bottom polystyrene tubes and incubated with
pooled mouse IgG (Sigma Aldrich, St. Louis, MO, USA) for 15
minutes at room temperature (RT). Subsequently, cells were
labelled with phycoerythrin (PE)- or peridinin-chlorophyll protein
complex (PerCP)-conjugated monoclonal antibodies (mABs)
specific for CD29, CD11b, CD105, CD34, CD117 (c-kit),
CD44, Ly6A/E (Sca-1) (all Biolegend, San Diego, CA, USA) as
wells as SSEA-4 (R&D Systems, Mineapolis, MN, USA), MHC
Class II (I-A/I-E), MHC Class I (H2D) and CD45 (all Becton
Dickinson Biosciences, San Jose, CA, USA) for 30 minutes at 4uC
in the dark. PE- as well as PerCP-conjugated isotype-matched
mABs were used as negative controls. To asses cell viability Via-
Probe
TM Cell Viability solution (Becton Dickinson Biosciences,
San Jose, CA, USA) was added shortly before flow cytometric
analysis. Two additional washes were performed and cell surface
antigen expression was analyzed on a FACScan using Cell-
Quest
TM software (both BD Biosciences, San Jose, CA, USA) with
10,000 events recorded for each sample.
In vitro differentiation of GFP MSCs
Assessing the potential of isolated cells to differentiate into
osteogenic and adipogenic lineages was performed as previously
described [27]. Briefly osteogenic differentiation was induced
culturingMSCsin6-wellcultureplates(TPP,Trasadingen,Switzer-
land) in IMDM medium containing 10% FBS, 100 units/ml
penicillin and 100 mg/ml streptomycin and supplemented with
50 mM ascorbate 2-phosphate, 10 mM b-glycerol phosphate and
100 nM dexamethasone (all from Sigma Aldrich, St. Louis, MO,
USA). Mediumwaschanged twice a week fora periodof 2–3 weeks.
To observe calcium deposition, cultures were washed with PBS,
fixed with 4% paraformaldehyde (PFA, Sigma Aldrich, St. Louis,
MO, USA) for ten minutes and stained with Alizarin Red, pH 4.1,
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three times with PBS to reduce non-specific staining.
Adipogenic differentiation was induced after growing MSCs as
a monolayer and allowing them to become confluent. Complete
medium was exchanged to adipogenic induction medium
consisting of IMDM medium containing 10% FBS, 100 units/
ml penicillin and 100 mg/ml streptomycin, 1 mM dexamethasone
and 0.5 mM methyl-isobutylxanthine, 10 mg/ml insulin and
100 mM indomethacin (all from Sigma Aldrich, St. Louis, MO,
USA). Cells were incubated in this medium 48–72 hours and then
adipogenic maintenance medium containing 10 mg/ml insulin and
10% FBS in IMDM was applied for 24 hours. Cells were then
again treated for 48–72 hours with adipogenic induction medium
followed by a period of 24 hours in maintenance medium and a
third treatment with induction medium. Finally, cultures were kept
for one week in adipogenic maintenance medium. Cells were fixed
in 4% PFA and lipid droplet staining was performed using Oil Red
O (Sigma Aldrich, St. Louis, MO, USA).
Cell transplantation
For MSC transplantation, two groups of (PLP)-a-SYN mice
were included in the study, one group termed (PLP)-a-SYN+MSC
(n=12) receiving 500,000 cells in 150 ml of saline through the tail
vein, and the control group termed (PLP)-a-SYN (n=6) sham
injected with an equal amount of saline only. Survival in the (PLP)-
a-SYN+MSC group was around 60%.
Behaviour
To determine the efficacy of intravenously transplanted MSCs
with respect to a potential amelioration of motor dysfunction in
the (PLP)-a-SYN mouse modelling MSA [28], the following motor
function assessment was carried out: beam walking test and stride
length analysis with DigiGait.
Beam walking test. Fine motor coordination and balance
capabilities of mice were assessed by the beam walking test [29].
The beams consisted of long stripes of wood (each measuring
70 cm) with square cross sections of 0.9 cm and 1.6 cm,
horizontally placed 50 cm above the bench surface. The mice
were encouraged to walk a distance of 50 cm. For training, three
daily sessions of three trials (9 crossings) were performed using the
1.6 cm square large beam. Mice were then tested 1 week, 2 weeks
and 4 weeks post transplantation (p.t.) using the 0.9 cm square
beam. Mice were allowed up to 60 seconds to traverse the beam.
The latency to traverse the beam and the number of times the
hind feet slipped off, over the given distance of 50 cm, were
recorded for three consecutive runs. Analysis of each session was
based on the mean score of the three trials.
Stride length analysis with DigiGait. The DigiGait System
(DigiGait Imaging System, Mouse Specifics, Boston, MA, USA) is
a non-invasive method for quantitatively compare gait dynamics
[30]. Each mouse was placed on a transparent belt of a treadmill
enclosed by a plastic scaffold. The speed of the treadmill was set to
20 cm/s for all experimental groups. The ventral side of the mice
as they walk was imaged by a high-speed camera, which captured
the dynamics of the paws and corresponding limbs as they
approach and move away from the belt. A special software,
DigiGait Imaging System, Mouse Specifics, Boston, MA, USA)
automatically calculated stride length and other spatial and
temporal gait indices for each limb. DigiGait analysis was
performed at 1 week, 2 and 4 weeks p.t.
Tissue processing
Four weeks after MSC treatment, animals were transcardially
perfused with PBS under deep thiopental anaesthesia. Brains were
removed and cut to separate the hemispheres. One hemisphere
was put into 4% PFA overnight and cryoprotected with 20%
sucrose. Brains were slowly frozen and kept at 280uC for further
processing.
The other hemisphere was cut to obtain midbrain-brainstem
tissue, put into a cryovial (Nunc, Rochester, New York, USA) and
frozen in liquid nitrogen and stored at 280uC until use. A
modified RIPA buffer [31] was used to homogenize brain tissue of
each preparation. Brain homogenates were centrifuged at
16,000 g for ten minutes at 4uC and supernatants were stored at
280uC until further processing.
Immunohistochemistry
Six series of 40 mm sections throughout the whole hemisphere
were cut on a cryostat (Leica, Nussloch, Germany). One series was
directly mounted on gelatine-coated slides and used for cresyl
violet (Nissl) staining. Immunolabelling was performed on free
floating sections using the following antibodies: rat anti-mouse
CD11b (1:150; AbD Serotec, Oxford, UK), polyclonal rabbit anti-
green fluorescence protein (1:1000; GFP, Abcam, Cambridge,
UK), polyclonal rabbit CD3 (1:7500, Abcam, Cambrige, UK) and
monoclonal mouse anti-tyrosine hydroxilase (TH, 1:1000, Sigma,
St. Louis, MO, USA). Secondary antibodies were biotinylated
anti-rat IgG, biotinylated anti-rabbit IgG, anti-mouse IgG (1:200,
all Vector Laboratories, Burlingame, CA), Alexa-fluor 488-
conjugated goat anti-rabbit or Alexa-fluor 594-conjugated goat
anti-rat (both 1:500, Molecular Probes, Leiden), respectively.
Endogenous peroxidase activity was quenched in H2O2. After
normal serum blocking, sections were incubated with the primary
antibody overnight at 4uC, followed by incubation in biotinylated
secondary antibody. After incubation in Vectastain ABC reagent
(Vectastain ABC kit, Vector Laboratories, Burlingame, CA), the
immunohistochemical reaction was developed with 3,39-diamino-
benzidine (DAB) and sections were mounted onto gelatine-coated
slides, counterstained with cresyl violet or Mayer’s haematoxylin
solution, dehydrated and coverslipped with Entellan. Immunoflu-
orescence staining performed for tracing GFP positive MSCs was
carried out by normal serum blocking and overnight incubation
with the anti-GFP primary antibody followed by incubation with
the respective secondary antibody, and counterstaining of the
nucleus by 49, 6-Diamidin-29-phenylindoldihydrochlorid (DAPI,
Sigma Aldrich, St. Louis, MO, USA). For GFP staining, brain
sections from C57BL/6-Tg(UBC-GFP)30Scha/J mice were used
as positive controls and tissue sections from (PLP)-aSYN
transgenic animals as negative controls. Double-immunofluores-
cence staining for GFP and CD11b was performed as described
above; dilution of the commercial rat anti-mouse CD11b antibody
was 1:50.
Quantification of a-synuclein concentration in brain
lysates
Brain lysates were analysed for aSYN concentration using an a-
synuclein immunoassay kit (Invitrogen, Carlsbad, CA, USA),
following manufacturer’s instructions. ELISA plates were analysed
with a multi-well plate reader at 450 nm (Beckman Coulter, Brea,
CA, USA).
Quantification of cytokine concentrations in brain lysates
Brain lysates were analysed using the mouse Th1/Th2 10-plex
kit, MCP-1 and TGF-b1 (Flow Cytomix, Bender MedSystems,
Vienna, Austria) according to the manufacturer’s instructions.
Data were acquired using a FACScan (BD Biosciences, San Jose,
CA, USA) with 1500 events recorded for each sample and further
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MedSystems, Vienna, Austria).
Microscopy and image analysis technique
Cell culture microscopy was performed using a Leica DMI
4000B microscope and Application Suite V3.1 (Leica, Wetzlar,
Germany). Fluorescent histological sections were analysed with the
aid of an ApoTomeH microscope and AxioVision Software (both
Carl Zeiss Microimaging GmbH, Jena, Germany).
All morphometric analysis was done in a blinded way applying a
computer-assisted image analysis system (Nikon E-800 micro-
scope, CCD video camera, Optronics MicroFire, Goleta, USA;
Stereo Investigator Software, MicroBrightField Europe e.K.,
Magdeburg, Germany). The optical fractionator method [32,33]
was used to estimate the total number of neurons and microglia in
the substantia nigra pars compacta (SNc).
Statistics
All data are given as means 6 standard error of the mean
(SEM). Behavioural data were compared by two-way analysis of
variance (ANOVA) for time and treatment effects followed by a
post hoc Bonferroni test (corrected for multiple comparisons). Data
from cytokine measurements were subjected to two-tailed
unpaired Student’s t-test with regard to treatment. Data obtained
from image analysis technique were analysed by unpaired
Student’s t-test. Correlations between cytokines and the number
of TH
+ neurons were performed with the Pearson correlation
analysis. All statistical analyses were performed with GraphPad
Prism 5 Software (GraphPad Software Inc., San Diego, CA, USA).
A p-value of p,0.05 was considered significant.
Results
Isolation and characterization of murine GFP MSCs
MSCs of GFP transgenic mice were isolated from tibia and
femur and kept in culture for several passages. For characteriza-
tion, differentiation and transplantation, cells at passage 8 were
used (Figure S1, A). Before intravenous application the cells were
characterised, flow cytometry analysis confirmed that the cells at
the stage of transplantation were positive for GFP (96.65%), CD29
(98.72%), CD44 (99.51%), CD105 (99.43%), MHC Class I (H2D,
48.23%), Sca-1 (99.48%), SSEA-4 (95.91%) and had a low
number of CD11b (13.28%), CD34 (13.10%), CD45 (1.72%),
CD117 (c-kit, 15.76%) and MHC Class II (I-A/I-E, 11.84%). At
the stage of transplantation 99.92% of all cells were viable, as
revealed by Via Probe staining.
Multilineage potential was demonstrated by differentiation into
adipocytes, indicated by Oil-Red O staining (Figure S1, B)a s
well as calcium deposits indicating osteogenic lineage differenti-
ation when stained with Alizarin Red (Figure S1, C).
Cell transplantation and tracing of GFP MSCs
Two groups of aged (PLP)-a-SYN mice were included in the
study, one group receiving 500,000 cells/150 ml of saline through
the tail vein designated (PLP)-aSYN+MSC, and one group serving
as controls with an equal amount of saline only into the tail vein
termed (PLP)-aSYN. Immunofluorescence with a polyclonal
rabbit anti-GFP antibody was performed on PFA fixed MSCs in
culture (Figure 1A) to ensure tracing of GFP MSCs (Figure 1B).
Single engrafted donor cells were detected four weeks post MSC
injection in the (PLP)-aSYN+MSC group (Figure 1E and 1G)
whereas sections from PLP-aSYN mice served as negative controls
(Figure 1F and 1H). To control the efficiency of the antibody in
fixed tissue, brain sections from (PLP)-aSYN control group served
as negative control (Figure 1C) while brain sections from C57BL/
6-Tg(UBC-GFP)30Scha/J served as positive (Figure 1D) control.
In face of potential contaminations of myeloid cells (CD11b) in the
MSC culture, double staining with GFP and CD11b (Figure 1I, J
and K) was performed in sections of the (PLP)-aSYN+MSC group
to prove the phenotype of GFP positive cells being MSCs and not
myeloid cells.
Behaviour
The efficacy of intravenously transplanted MSCs to restore
motor function in aged (PLP)-aSYN mice versus controls, was
measured with the beam walking test, and stride length was
analysed with the DigiGait system. The beam walking test
determines fine motor coordination and balance capabilities.
Traversing the beam was performed 1 week, 2 and 4 weeks p.t.
Over the period of 4 weeks, no significant improvement in the
time traversing the beam (Figure 2A)( p .0.05) or in the number
of sideslips (Figure 2B)( p .0.05) was detected.
We analysed the stride length on both hindlimbs (left, right) with
the DigiGait System in the transplant and control group. Previous
results from our research group have demonstrated that (PLP)-
aSYN transgenic mice show shortening of hindlimb stride length
associated with TH
+ cell loss in the SNc [28]. In the current study
we analysed the stride length of the left (Figure 2C) and right
(Figure 2D) hindlimbs in the transplant and control group at 1
week, 2 week and 4 weeks p.t. Stride length in animals treated with
i.v. MSCs was not significantly altered from stride length in the
control group (for both hindlimbs p.0.05).
Both tests demonstrate that i.v. MSC treatment in aged (PLP)-
aSYN mice has not induced changes in motor behaviour.
Neuroprotective effect on TH
+ neurons in the SNc after
MSC treatment
Reduction of TH-immunoreactive neurons was previously
reported in the SNc of (PLP)-aSYN transgenic mice [28] suggesting
that the presence of aSYN in oligodendrocytes induces dopami-
nergic neuron loss. We performed TH staining and stereological
counting in the SNc in the MSC treatment and control group
(Figure 3A–3E) demonstrating a significant recovery of the total
number of TH
+ neurons in the MSC treated group ((PLP)-
aSYN+MSC 47476356.8 vs. (PLP)-aSYN 35106368.8; p=0.036)
4 weeks after transplantation.
aSYN concentration in midbrain-brainstem lysates
In previous studies, research on the (PLP)-a-SYN mouse model
has demonstrated that pathological aSYN accumulation promotes
degeneration of neurons in the SNc, locus coeruleus, nucleus
ambiguous, laterodorsal tegmental nucleus, pedunculopontine
nucleus and Onuf’s nucleus [34,35] similar to findings in MSA
patients (reviewed in [2]). With a aSYN immunoassay we
investigate whether MSC treatment had an effect on aSYN
concentration in midbrain-brainstem lysates. We chose midbrain-
brainstem samples (Figure 4A) since the dissected area includes the
affected nuclei. Statistical analysis by unpaired Student’s t-test did
notshowdifferenceson aSYNconcentrationin MSC treated(n=7)
versus control animals (n=6) ((PLP)-a-SYN+MSC 1.89960.1032
vs. (PLP)-a-SYN 1.69260.1322, p=0.237) (Figure 4B).
MSCs influence cytokine levels in midbrain-brainstem
lysates
IL-1a, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, GM-CSF, INFc,
MCP-1, TGF-b1 and TNFa were assessed in midbrain-brainstem
lysates of (PLP)-aSYN+MSC versus (PLP)-aSYN animals. Four
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+ MSCs in aged (PLP)-aSYN transgenic mice. (A) GFP
+ MSCs in culture showed diffuse
green fluorescence which could be further enhanced by immunocytochemistry using GFP antibody (B). To control the same GFP antibody in brain
sections, negative- ((PLP)-aSYN mice, C) and positive (C57BL/6-Tg(UBC-GFP)30Scha/J transgenic mice, D) tissue sources were applied. Scale bars (A,
B, C, D) represent 50 mm. Single GFP
+ MSCs could be observed, throughout the brain in transplanted animals, by ApoTome confocal-like images of
SN (E) and brainstem (G). Negative control sections of GFP staining in (PLP)-aSYN mice of SN (F) and brainstem (H). Scale bars (E, F, G, H) represent
20 mm. Arrows indicate GFP
+ MSCs. ApoTome confocal-like images of GFP (I) and CD11b positive cells (J) in PLP-aSYN+MSC mice. The merged image
(K) indicates that GFP
+ cells do not colocalize with CD11b
+ cells. Asterisk indicate GFP
+ cells, circle indicates CD11b
+ cell. Scale bars (I, J, K) represent
20 mm. GFP, green fluorescent protein; SN, substantia nigra.
doi:10.1371/journal.pone.0019808.g001
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downregulation of IL-1a (p=0.0014), IL-2 (p=0.019), IL-10
(p=0.046), IL-17 (p=0.056), GM-CSF (p=0.029), TGF-b1
(p=0.001) and TNFa (p=0.001) (Figure 5A - 5G) in midbrain-
brainstem lysates of MSC treated animals versus control group,
whereas no significant difference was found for IL-4 (p=0.16),
MCP-1 (p=0.18), IL-5 (0.072), IL-6 (p=0.18) and INFc (p=0.31).
Due to a significant reduction of the lymphocytic signalling
molecules IL-2 and IL-17, we performed a staining for the T-cell
marker CD3 in (PLP)-aSYN+MSC and (PLP)-aSYN animals. We
could detect single CD3
+ cells throughout different brain regions
(Figure 5H–5K).
Moreover, we analysed microglia as an additional source of
cytokines. Previous work of our group has shown that microglial
activation in the (PLP)-aSYN mouse is present in the SNc and
mediates neurodegeneration [34]. Hence counting CD11b-
immunoreactive cells in the SNc as a marker for microglia was
performed (Figure S2, B–C). Statistical analysis with two-tailed
unpaired Student’s t-test, revealed no significant difference in the
number of CD11b
+ cells in transplanted animals (n=7) versus the
control group (n=6) ((PLP)-aSYN+MSC 65886242 vs. (PLP)-
aSYN 68806529.3; p=0.6075) (Figure S2, A).
Finally, in order to evaluate whether the cytokines in midbrain-
brainstem lysates (IL-1a, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, GM-
CSF, INFc, MCP-1, TGF-b1 and TNFa) contribute to TH
+
neuronal rescue we established a Pearson correlation between the
cytokines and TH
+ neurons (Table 1). We could demonstrate
significant inverse correlations for IL-1a (Pearson r=20.697,
p=0.0081), IL-2 (Pearson r=20.823, p=0.0005), TGF-b1
(Pearson r=20.647, p=0.0169) and TNFa (Pearson
r=20.0575, p=0.0397).
Discussion
In the present study we aimed to determine whether
intravenous application of murine MSCs in an aged (PLP)-aSYN
MSA mouse model ameliorates behavioural deficits and exerts
neuroprotective and immunomodulatory properties. To date, to
our knowledge there is no experimental evidence of a MSC
therapeutic approach in transgenic MSA models. Recently,
human MSCs have been demonstrated to protect against loss of
neurons in SN and striatum in an animal model of double toxin-
induced MSA-P [23]. A few years ago, in an open-label study
design, disease modifying effects of intra-arterial and intravenous
injected MSCs in eleven patients with MSA-C, have been reported
[22]. Together with in vitro and in vivo findings in PD and other
neurodegenerative disorders, MSCs seem to be an attractive and
feasible therapeutic intervention [20,23,36–39].
As a matter of fact, experimental results are often difficult to
compare, in lieu of standards for MSC isolation, cultivation and in
vivo application. Furthermore there is no unique marker to
Figure 2. Assessing motor coordination with the beam walking test and DigiGait analysis. Duration to traverse a narrow beam analysed 1
week, 2 weeks and 4 weeks post transplantation (p.t.) (A). No difference between (PLP)-aSYN (n=6) and (PLP)-aSYN+MSC (n=7) treated animals was
found (p.0.05). Number of side slips traversing a 50 cm narrow beam was analysed at 1 week, 2 weeks and 4 weeks p.t. (B). Statistical analysis did
not reveal any significant difference between both groups. Stride length analysis of left (C) and right (D) hindlimbs of (PLP)-aSYN+MSC (n=7) versus
(PLP)-aSYN controls (n=6), 1 week, 2 weeks and 4 weeks p.t. Stride length did not significantly alter in MSC treated animals compared to saline
treated controls (p.0.05). Data were analysed by two-way ANOVA, following Bonferroni post-hoc test (for multiple corrections) and are presented as
means 6 SEM. Statistical significance was set at p,0.05.
doi:10.1371/journal.pone.0019808.g002
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expression of a group of surface receptors and upon their
multilineage potential [40]. Prior to transplantation we have
characterized GFP MSCs, based on a set of criteria proposed by
the International Society for Cellular Thearpy [41], which
includes expression and lack of surface markers and differentiation
potential into adipocytes and osteocytes.
In the (PLP)-aSYN+MSC transplant group the survival rate
after intravenous MSC infusion was low, probably due to the high
age of the animals. Further we presume that due to their size
MSCs got trapped within the pulmonary capillaries, causing
pulmonary and hemodynamic alterations [42]. On the other hand
numerous animal studies and clinical trials have reported
favourable outcomes following systemic infusion of MSCs [36,43].
Since we have only encountered a few single donor engrafted
GFP
+ MSCs four weeks after transplantation, the use of GFP as
experimental tool to examine the survival and fate in future studies
is in question, since there are a lot of inconsistent results in the
literature, on tracking and determining cell fate of MSCs using
GFP as a reporter in transplantation studies [44,45]. In addition,
we cannot exclude a detrimental effect of the GFP protein on
MSC survival and therefore preventing proper integration into
sites of neurodegeneration. On the other hand, a number of
reports state that MSCs exert effects on tissue repair despite
exhibiting low and/or transient levels of engraftment [20,40]. This
foreshadows a novel concept of tissue repair relying on secretion of
trophic factors and/or crosstalk with the microenvironment rather
than MSC transdifferentation.
The (PLP)-aSYN transgenic mouse model has been widely
characterized in terms of effects of aSYN overexpression on
neurodegeneration and motor activity [28,35]. Furthermore, this
animal model has been successfully applied in neuroprotective
studies as a preclinical rationale for phase II clinical trials [46,47].
We performed the beamwalking test to define fine motor
coordination and balance capabilities as well as stride length with
a digital system, since shortening of the stride length has been
reported in the (PLP)-aSYN transgenic mouse [28]. In a recent
study, intravenous human MSCs have ameliorated behavioural
deficits in a double-toxin induced mouse model of MSA-P [23].
Our experimental data show no significant effects of intravenously
applied MSCs to alleviate behavioural failure. On the other hand,
the study with double-toxin induced striatonigral degeneration has
been performed in mice lacking aSYN expression in oligoden-
droglia and thus replicating solely striatonigral-like pathology
without reproducing other cardinal features of MSA. It remains
elusive whether oligodendroglial aSYN exerts a deleterious effect
on transplanted MSCs, however in a recent study addressing the
fate of embryonic striatal grafts in presence of oligodendroglial
aSYN inclusions, disturbed dopaminergic re-innervation and
Figure 3. Neuroprotection of dopaminergic neurons in SNc
after MSC treatment of (PLP)-aSYN mice. Quantification of TH-
immunoreactive neurons in the SNc demonstrating a significant survival
of TH
+ neurons (p=0.036) in animals with MSC treatment compared to
controls, four weeks after i.v. MSC transplantation (A). Low magnifica-
tion of TH immunohistochemistry, counterstained with Nissl in (PLP)-
aYN (B) and (PLP)-aSYN+MSC treated animals (C). Scale bar (A,B)
represent 300 mm. High magnification of TH neurons in SNc of Tg (D)
and Tg+MSC treated animals (E). Scale bar (D,E) represent 20 mm. Cell
counts were analysed by unpaired Student’s t-test and the level of
significance was set at p,0.05 (* p,0.05). Data are presented as means




Figure 4. aSYN concentration is not altered in midbrain-
brainstem lysates of MSC treated mice. aSYN concentrations in
midbrain-brainstem lysates (A) were determined for the (PLP)-aSYN
(n=6) and (PLP)-aSYN+MSC (n=7) group by ELISA. Student’s unpaired
t-test revealed no significant difference between both groups
(p=0.237) (B). Data are presented as means 6 SEM with statistical
significance p.0.05.
doi:10.1371/journal.pone.0019808.g004
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been attributed to effects of host aSYN pathology [48].
For our pilot study, we have chosen transgenic animals at the
age of 18 months, overexpressing aSYN under control of the
PLP promoter, since GCIs are the hallmark of MSA and MSA is
a late onset disease [49,50]. Previous studies have clearly
demonstrated that in this MSA animal model aSYN overex-
pression leads to neurodegeneration [28,35] resembling human
neuropathology. At the age of 18 months, neurodegeneration
due to aSYN overexpression is at a much more progressed
stage, impairing motor activity drastically as shown in MSA
mouse models overexpressing aSYN under control of oligoden-
droglial promoters [51,52]. Currently we are examining this
issue more closely in the (PLP)-aSYN mouse. Nevertheless, the
absent behavioural improvement after MSC treatment, leads
to the conclusion, that MSC treatment at later disease stages
d o e sn o ti n d u c et h ed e s i r e de f f e c to fa m e l i o r a t i n gb e h a v i o u r a l
deficits.
Since one pathological feature in MSA patients covers selective
neuronal loss in the SNc, and the (PLP)-aSYN mouse model
replicates this feature, we evaluated whether MSC treatment had
an effect on number of TH
+ neurons. There was a subtle but
significant recovery of numbers of dopaminergic neurons in the
MSC transplant group compared to transgenic controls.
We further investigated putative factors that may contribute to
this ‘‘rescue’’ of dopaminergic neurons after MSC treatment. We
analysed whether TH recovery is caused by the decrease of aSYN
concentration in midbrain-brainstem lysates. aSYN is known to be
a key factor involved in oligodendroglial and neuronal loss in MSA
patients and in the (PLP)-aSYN transgenic animal model
[3,28,34,35]. Recently genetic variants in the aSYN gene SNCA
have been associated with an increased risk in developing MSA
Figure 5. Influence of MSC treatment on cytokine concentrations in midbrain-brainstem lysates. Cytokine levels in midbrain-brainstem
lysates were quantified by flow cytometry. Significant downregulation of IL-1a (p=0.0014) (A), IL-2 (p=0.019) (B), IL-10 (p=0.046) (C), IL-17
(p=0.056) (D), GM-CSF (p=0.029) (E), TGF-b1 (p=0.001) (F) and TNFa (p=0.001) (G) in MSC treated animals (n=7) versus controls (n=6) was
observed. All data are presented as means 6 SEM and were analysed by the Student’s unpaired t-test.( *p ,0.05; ** p,0.01; *** p,0.001).
Representative CD3
+ stainings counterstained with Mayer’s haematoxylin solution demonstrated invading T-cells throughout the brain, as presented
here in hippocampus (H), striatum (I), substantia nigra pars compacta (J) and cortex (K) in (PLP)-aSYN transgenic animals. A similar staining pattern
was observed in (PLP)-aSYN+MSC treated animals. Scale bar (H, I, J, K) represents 10 mm. Asterisk indicate CD3
+ T-cells. Hi, hippocampus; Str,
striatum, SNc, substantia nigra pars compacta; Ctx, cortex.
doi:10.1371/journal.pone.0019808.g005
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region was not significantly altered between (PLP)-aSYN+MSC
treatment compared to (PLP)-aSYN control group. This finding
highlights the concept of tissue repair of MSCs by releasing anti-
inflammatory and trophic molecules.
Neuroinflammation has been widely regarded as a possible key
player in progressing disease pathogenesis in various neurodegen-
erative diseases. In PD patients as well as PD animal models,
neuroinflammation in terms of microglial activation has been
observed [9]. Lately emerging evidence for the presence of T-
lymphocytes in the midbrain of PD patients suggests that a potential
role of infiltrated peripheral cells is related to PD pathogenesis
[9,55]. In a recent study infiltration of T-cells into the brain actively
participated in dopaminergic neuron degeneration in the SNc [56].
Additionally, overexpression of human aSYN in mouse SN
neurons, induced by an adeno-associated viral vector, has led to
activation of microglia, production of inflammatory cytokines and
stimulated the adaptive immune response [57]. In our experiment
we analysed twelve cytokines, IL-1a, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-17, GM-CSF, INFc, MCP-1, TGF-b1 and TNFa in midbrain-
brainstem lysates and found significant downregulation of IL-1a,
IL-2, IL-10, IL-17, GM-CSF, TGF-b1 and TNFa four weeks after
intravenous MSC application in the treatment group. Additionally
we encountered CD3
+ T-cells throughout the brain in (PLP)-aSYN
and (PLP)-aSYN+MSC treated animals. After MSC treatment,
however, the T-cell specific cytokines IL-2 and IL-17 were
significantly downregulated. Furthermore, TH neuronal ‘‘rescue’’
was inversely correlated with IL-2, indicating that MSC treatment
influenced pathogenic T-cell response in (PLP)-aSYN mice. Similar
effects have been widely investigated for multiple sclerosis and
experimental autoimmune encephalitis and support the role of
MSC treatment by modulation of T-cell response [58].
Finally we analyzed the influence of MSC treatment on
microglial activation, since microglia have been reported to
parallel the neuronal multisystem degeneration in MSA [8] and
mediates dopaminergic neuronal loss related to oligodendroglial a-
synucleinopathy in the (PLP)-aSYN mouse [34]. We quantified
the number CD11b
+ microglial cells in the SNc, yet could not
demonstrate a significant difference in microglial cell number after
MSC treatment. However, this finding cannot exclude a
modulatory effect on microglial activation status. Furthermore,
the major proinflammatory cytokine TNFa and IL-1a, also
released by activated microglia and astroglia was significantly
decreased in brain lysates of the MSC treatment group and
inversely correlate with the number of TH neurons indicating that
suppression of microglial activation and astrogliosis may contrib-
ute to dopaminergic neuronal survival. Similar results, demon-
strating decreased activation of astrocytes and microglia by human
MSCs in a mouse model of MSA-P have been recently reported
[23] and are in good concordance with our findings that MSCs
exert modulatory effects on neuroinflammation and promote
survival of dopaminergic neurons in the SNc.
In summary, our study describes the first experimental attempt
using MSCs as a therapeutic intervention in an aged transgenic
mouse model of MSA featuring oligodendroglial a-synucleino-
pathy. We have demonstrated that intravenous application of
MSCs leads to a rescue of dopaminergic neurons in the SNc.
Furthermore we could demonstrate a profound immunomodula-
tory effect after MSC treatment, resulting in downregulation of
various proinflammatory cytokines, which are linked to microglial
activation, astrogliosis and mediation of adaptive immunity.
However, MSC treatment did not alter behavioural deficits in
aged transgenic MSA mice.
Our data have potential implications for MSCs as a future stem
cell source in MSA therapies. Nevertheless, further experimental
studies on the efficacy of MSCs as disease modifying candidates in
MSA as well as different routes of application have to be
performed. Prior to embarking on further human trials, preclinical
studies are necessary since they will reveal if all that glitters
experimentally is truly clinical gold.
Supporting Information
Figure S1 Differentiation of MSCs into adipocytes and
osteocytes. After applying lineage specific induction media,
MSCs (A) differentiated into adipocytes, demonstrated by presence
of Oil-Red O lipid droplet staining (B). Differentiation into the
osteogenic lineage was demonstrated by Alizarin Red staining,
identifying calcification of cells (C). Scale bar (A) represents 20 mm,
scale bars (B,C) represent 50 mm.
(TIF)
Figure S2 MSC treatment had no effect on the number
of CD11b
+ microglial cells. Quantification of CD11b
+
microglial cells by stereological counting demonstrated that four
weeks after MSC treatment the number of CD11b
+ cells was not
significantly altered in the treatment group compared to controls
(p=0.6075) (A). All data are presented as means 6 SEM and were
analysed by unpaired Student’s t-test. Immunohistochemical
staining of CD11b
+ microglial cells in the SNc of a (PLP)-aSYN
(n=6) (B) and (PLP)-aSYN+MSC (n=7) mouse (C). Scale bars
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Table 1. Correlation between cytokines and TH neurons.
Cytokine Pearson r p-value Significance
IL-1a 20.6970 0.0081 **
IL-2 20.8234 0.0005 ***
IL-4 20.1205 0.6950 n.s.
IL-5 20.4112 0.1628 n.s.
IL-6 20.5122 0.0735 n.s.
IL-10 20.5149 0.0718 n.s.
IL-17 20.3720 0.2106 n.s.
GM-CSF 20.3958 0.1806 n.s.
INFc 20.01089 0.9718 n.s.
MCP-1 20.4772 0.0992 n.s.
TGF-b1 20.6465 0.0169 *
TNFa 20.5752 0.0397 *
Abbreviations: interleukin-1alpha (IL-1a), interleukin-2 (IL-2), interleukin-4
(IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-10 (IL-10),
interleukin-17 (IL-17), granulocyte macrophage colony-stimulating factor (GM-
CSF), interferon gamma (INFc), monocyte chemotactic protein-1 (MCP-1),
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